A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.

This publication has 35 references indexed in Scilit:

• Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
  European Journal Of Cancer, 1996
• Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy
  Cancer Chemotherapy and Pharmacology, 1995
• The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis.
  1994
• 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study
  European Journal Of Cancer, 1993
• Tropisetron
  Drugs, 1993
• Are all 5-HT3 receptor antagonists the same?
  European Journal Of Cancer, 1992
• Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study
  British Journal of Cancer, 1992
• 5-HT3 Receptor Antagonists
  Drugs, 1991
• The concept of selectivity in 5-HT receptor research
  European Journal of Pharmacology: Molecular Pharmacology, 1990
• MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors
  Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1984